title: A small-molecule factor XIa inhibitor produces antithrombotic efficacy with minimal bleeding time prolongation in rabbits.
abstract: BMS-262084 is a 4-carboxy-2-azetidinone-containing irreversible inhibitor of FXIa, which is selective over other coagulation proteases. We evaluated the in vitro and in vivo properties of BMS-262084 in rabbits. Studies were conducted in arteriovenous-shunt thrombosis (AVST), venous thrombosis (VT), electrolytic-mediated carotid arterial thrombosis (ECAT) and cuticle bleeding time (BT) models. BMS-262084 was infused IV from 1 h before thrombus induction or cuticle transection to the end of the experiment. In vitro, BMS-262084 prolonged activated partial thromboplastin time (aPTT) with EC(2x) (concentration required to double aPTT) of 10.6 μM in rabbit plasma, and did not prolong prothrombin time (PT), thrombin time (TT) and HepTest. In vivo, BMS-262084 produced dose-dependent antithrombotic effects in rabbits with antithrombotic ED(50) (dose that reduced thrombus weight or increased blood flow by 50% of the control) in AVST, VT and ECAT of 0.4, 0.7 and 1.5 mg/kg/h IV, respectively. BMS-262084 increased ex vivo aPTT dose-dependently without changes in PT and TT. The antithrombotic effect of BMS-262084 was significantly correlated with its ex vivo aPTT, supporting the use of ex vivo aPTT as a pharmacodynamic biomarker. BMS-262084 did not alter ex vivo rabbit platelet aggregation to ADP and collagen. BT (fold-increase) determined at 3 and 10 mg/kg/h of BMS-262084 were 1.17 ± 0.04 and 1.52 ± 0.07*, respectively (*P < 0.05 vs. control). This study demonstrated that BMS-262084 prevented experimental thrombosis at doses with low BT effects in rabbits, and suggests that a small molecule FXIa inhibitor may represent a promising antithrombotic therapy.
authors: Cardiovascular Biology, Bristol-Myers Squibb Company, 311 Pennington-Rocky Hill Road, Pennington, NJ 08534, USA. pancras.wong@bms.com
authors: Pancras C
authors: PC
authors: Wong
authors: Earl J
authors: EJ
authors: Crain
authors: Carol A
authors: CA
authors: Watson
authors: William A
authors: WA
authors: Schumacher
references: Tech Vasc Interv Radiol. 2002 Jun;5(2):85-8
references: 12489046
references: Bioorg Med Chem Lett. 2002 Nov 4;12(21):3229-33
references: 12372540
references: J Pharmacol Exp Ther. 2000 Jan;292(1):351-7
references: 10604970
references: Thromb Haemost. 1994 Mar;71(3):357-62
references: 8029801
references: J Thromb Haemost. 2007 Jun;5(6):1106-12
references: 17388803
references: Am J Clin Pathol. 1990 Sep;94(3):297-306
references: 2396604
references: Thromb Haemost. 1991 Mar 4;65(3):268-74
references: 1710836
references: Bioorg Med Chem Lett. 2006 Oct 1;16(19):5022-7
references: 16876411
references: Bioorg Med Chem Lett. 2006 Jun 1;16(11):3049-54
references: 16524727
references: Expert Rev Cardiovasc Ther. 2011 Mar;9(3):279-86
references: 21438804
references: Blood. 2003 Aug 1;102(3):953-5
references: 12689935
references: Blood. 2009 Jul 23;114(4):881-90
references: 19372258
references: J Thromb Haemost. 2006 Sep;4(9):1982-8
references: 16961605
references: J Pharmacol Exp Ther. 2000 Oct;295(1):212-8
references: 10991981
references: Arterioscler Thromb Vasc Biol. 2010 Mar;30(3):388-92
references: 20139363
references: Blood. 2010 Nov 11;116(19):3981-9
references: 20634381
references: Thromb Res. 2010 May;125(5):464-70
references: 20089298
references: Thromb Haemost. 2002 Apr;87(4):774-6
references: 12008966
references: Biomaterials. 1994 Jan;15(1):35-7
references: 8161655
references: ACS Chem Biol. 2009 Apr 17;4(4):249-60
references: 19193052
references: J Med Chem. 2006 Dec 28;49(26):7781-91
references: 17181160
references: Arterioscler Thromb Vasc Biol. 2007 Aug;27(8):1687-93
references: 17556654
references: Thromb Haemost. 1997 Sep;78(3):1142-9
references: 9308768
references: Thromb Haemost. 2010 Jul;104(1):49-60
references: 20539909
references: Thromb Haemost. 2011 Jan;105(1):161-8
references: 20941458
references: Eur J Pharmacol. 2007 Sep 10;570(1-3):167-74
references: 17597608
references: J Med Chem. 2008 Jun 26;51(12):3583-7
references: 18510371
references: J Pharmacol Toxicol Methods. 2000 Mar-Apr;43(2):101-16
references: 11150738
references: J Thromb Haemost. 2009 Aug;7(8):1313-20
references: 19500242
references: Proc Natl Acad Sci U S A. 2006 Jan 24;103(4):903-8
references: 16410357
references: Thromb Res. 2003;112(3):167-74
references: 14967414
references: Thromb Haemost. 2010 Jan;103(1):62-70
references: 20062934
references: J Thromb Haemost. 2006 Jul;4(7):1496-501
references: 16839345
references: Thromb Haemost. 2009 Jan;101(1):108-15
references: 19132196
references: Annu Rev Physiol. 1977;39:373-89
references: 322600
references: J Thromb Haemost. 2009 Jul;7 Suppl 1:84-7
references: 19630775
references: J Thromb Haemost. 2005 Apr;3(4):695-702
references: 15733058
references: Chest. 2008 Jun;133(6 Suppl):160S-198S
references: 18574265
references: Biomaterials. 2009 Sep;30(27):4447-56
references: 19535136
references: J Thromb Haemost. 2009 Jul;7 Suppl 1:79-83
references: 19630774
references: FEBS J. 2006 May;273(9):1871-95
references: 16640553
references: Blood. 2009 Jan 22;113(4):936-44
references: 18945968
references: N Engl J Med. 2009 Sep 17;361(12):1139-51
references: 19717844
references: J Thromb Haemost. 2008 May;6(5):820-9
references: 18315548